Durvalumab and tremelimumab demonstrated antitumor activity in patients with non-small cell lung cancer regardless of PD-L1 status.
Jason M. Broderick, OncLive
Advertisement
Articles by Jason M. Broderick, OncLive
Durvalumab and tremelimumab demonstrated antitumor activity in patients with non-small cell lung cancer regardless of PD-L1 status.
Advertisement
Latest Updated Articles
Lung Cancer Combination Therapy Shows PromisePublished: February 16th 2016 | Updated:
Combination Therapy Shows Promise in Lung CancerPublished: February 16th 2016 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
COVID-19 mRNA Vaccines May Boost Immunotherapy Response in Cancer
2
FDA, HHS Move to Accelerate Biosimilar Approvals
3
Accelerated Approval of Cancer Drugs: Benefit or Burden?
4
Recognizing Immunizing Pharmacists in the Community
5
